Unravelling glioblastoma heterogeneity by means of single-cell RNA sequencing

Cancer Lett. 2022 Feb 28:527:66-79. doi: 10.1016/j.canlet.2021.12.008. Epub 2021 Dec 10.

Abstract

Glioblastoma (GBM) is the most invasive and deadliest brain cancer in adults. Its inherent heterogeneity has been designated as the main cause of treatment failure. Thus, a deeper understanding of the diversity that shapes GBM pathobiology is of utmost importance. Single-cell RNA sequencing (scRNA-seq) technologies have begun to uncover the hidden composition of complex tumor ecosystems. Herein, a semi-systematic search of reference literature databases provided all existing publications using scRNA-seq for the investigation of human GBM. We compared and discussed findings from these works to build a more robust and unified knowledge base. All aspects ranging from inter-patient heterogeneity to intra-tumoral organization, cancer stem cell diversity, clonal mosaicism, and the tumor microenvironment (TME) are comprehensively covered in this report. Tumor composition not only differs across patients but also involves a great extent of heterogeneity within itself. Spatial and cellular heterogeneity can reveal tumor evolution dynamics. In addition, the discovery of distinct cell phenotypes might lead to the development of targeted treatment approaches. In conclusion, scRNA-seq expands our knowledge of GBM heterogeneity and helps to unravel putative therapeutic targets.

Keywords: Glioblastoma; Intra-tumoral heterogeneity; Single-cell analysis; Tumor microenvironment (TME); scRNA-seq.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Genetic Heterogeneity
  • Glioblastoma / genetics*
  • Humans
  • RNA-Seq / methods*
  • Single-Cell Analysis / methods*